Safety and Tolerability of Tedizolid as Oral Treatment for Bone and Joint Infections
Results. To date, we have enrolled 19 subjects (17 (89%) male) with BJIs (11 (58%) hardware associated infection, 5 (26%) osteomyelitis without prosthesis, 3 (16%) prosthetic joint infection). Significant comorbidities include six (32%) with diabetes and one (5%) with systemic lupus. Fourteen (74%) patients have completed therapy, two (11%) remain on therapy, one (5%) withdrew from the study, and two (11%) were lost to follow-up. Mean (median) duration of treatment has been 9.7 (11) weeks with a range of 4-12 weeks. Significant drug-related adverse events occurred in two patients (11%), both with non-life-threatening maculopapular rashes, one of whom required treatment discontinuation. To date, there have been 10/14 (71%) treatment successes. Failures have been associated with previously undetected retained hardware (n = 1), sequestrum requiring surgery (n = 1), and failure to achieve cure after the designated treatment course (n = 2). There have been no cases of cytopenias, peripheral or optic neuropathy.
Conclusion. Tedizolid appears to be a well-tolerated oral antibiotic for the treatment of bone and joint infections for 4 weeks or greater. Clinical failure rates appear roughly similar to that of other oral options. Further study of tedizolid for BJIs is warranted.
Disclosures. L. G. Miller, Merck: Grant Investigator, Research grant. Methods. This is a retrospective cohort study including adults determined to have native spondylodiskitis at our institution from January 2007 through July 2017. Inclusion criteria were imaging suggestive of spondylodiskitis, with either positive blood culture and/or a spinal biopsy culture or histopathology. Those with historical diagnosis or surgical site infections were excluded. Histopathology was the gold standard test for sensitivity/specificity calculation. Univariate logistic regression was used to predict positive biopsy culture.
Evaluation of the Diagnostic Approach to Native Spondylodiskitis
Results. A total of 221 patients met our inclusion criteria, of which 203 (91.8%) had blood cultures done (112/203 positive, 55.2%), and 173 (78.2%) had spinal biopsy done of which 113 (65.0%) had received antibiotics within the preceding 2 weeks and 63 (36.4%) had positive culture. Forty-three bone specimens were cultured, and six (13.9%) were positive, while 136 disk specimens were cultured, and 58 (42.6%) were positive. There were 84 (48.5%) biopsies with histopathology performed on either bone or disk specimens, of which 47 (55.9%) were diagnostic. The sensitivity of bone culture was 27.3%, with a specificity of 91.7%. The sensitivity of disk culture was 52.6%, with a specificity of 75.0%. A single biopsy episode sensitivity was 48.9%, and specificity was 80.8%. A total of 23 (13.4%) patients had repeat biopsies (10 bone, 14 disk), five of which had positive cultures (21.7%). On univariate logistic regression, only a positive blood culture was predictive of a positive biopsy culture (odds ratio (OR) 13.08, 95% confidence interval (CI) 1.97-86.81, P = 0.007). Disk culture had a higher yield than bone culture (OR 2.29; CI 0.91-5.73, P = 0.077) and prior antibiotics decreased the yield (OR 0.17; 95% CI 0.02-1.21, P = 0.078).
Conclusion. The combination of histopathology and cultures including both bone and disk from spinal biopsies improve the diagnostic yield of native spondylodiskitis. Some patients require repeat biopsy. 
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